|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||26.23 mL||131.15 mL||262.31 mL|
|0.5 mM||5.25 mL||26.23 mL||52.46 mL|
|1 mM||2.62 mL||13.12 mL||26.23 mL|
|5 mM||0.52 mL||2.62 mL||5.25 mL|
*The above data is based on the productmolecular weight 381.23. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
|Synonyms||WAY-EKI 785, CL387785, CL 387785, EKI785, WAY-EKI785, EKI 785, EKI-785|
Canertinib (CI-1033) is an irreversible tyrosine-kinase inhibitor with activity against EGFR (IC50 0.8 nM), HER-2 (IC50 19 nM) and ErbB-4 (I…
Mubritinib (TAK 165) is a potent EGFR and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Mubritinib(TAK 165) also inhibits p…
PD158780 is a very potent inhibitor of EGFR with IC50 of 0.08 nM; pan-specific antagonist of ErbB receptor.
WZ8040 is a novel EGFR inhibitors that suppress the growth of EGFR-T790M-containing cell lines and inhibit EGFR phosphorylation.
ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including Erb…
Pelitinib (EKB-569) is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity.
PF299804 is a potent, orally available, irreversible inhibitor of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HE…